Zusammenfassung
Non-peptid-Angiotensin-II-Typ-l-(AT1)-Rezeptorantagonisten stellen eine Klasse von sehr wirksamen Medikamenten dar, die das Potential besitzen, die medikamentöse Therapie der arteriellen Hypertonie und der chronischen Herzinsuffizienz zu erweitern. Bei Patienten mit manifester arterieller Hypertonie ist die Langzeittherapie mit Losartan (50–200 mg/Tag) effektiv, um den Blutdruck auf physiologische Werte zu senken und pathologische Umbauprozesse („Remodeling“) im Myokard und dem Gefäßsystem zu verhindern. Bei chronischer Herzinsuffizienz zeigten experimentelle Untersuchungen und Studien mit Patienten nach Myokardinfarkt, daß die Therapie mit dem Non-peptid-AT1-Rezeptorantagonisten Losartan (25–100 mg/Tag) nahezu äquipotent ist im Vergleich zu ACE-Inhibitoren (beispielsweise Enalapril 20 mg/Tag).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Baumann G (1996) ACE Inhibition after Myocardial Infarction. In: Tan LB, Ball SG (eds) ACE Inhibition. Science Press Limited, London, pp 7–12
Bedecs K, Elbaz N, Sutren M, Masson M, Susinin C, Strosberg D, Nahimias C (1997) Angiotensin II Type 2 receptor mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phopshtase. Biochem J 325: 449–454
Bunkenburg B, van Amelsvooit T, Rogg H, Wood JM (1992) Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle eels from spontaneously hypertensive rats. Hypertens 20: 746–754
Crozier I, Ikram H, Awan N (1995) Losartan in heart failure: hemodynamic effects and tolerability. Circuladon 91: 691–697
Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J (1995) Comparison of the effects of Losartan and Enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438–445
Dickstein K, Gotdieb S, Fleck E, Kosds J, Levine B, Dock M, Lemtel T (1994) Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens Suppl 12: 31–35
Gohlke P, Pees C, Unger T (1998) AT2 receptor stimulation increases aortic MP in SHRSP by a kinin- dependent mechanism. Hypertension 31: 349–355
Gotdieb SS, Dickstein K, Fleck E, Kosds J, Levine TB, Lemtel T, Dock M (1993) Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circuladon 88: 1602–1609
Ishida M, Marrero MB, Schieffer B, Bernstein KE, Berk BC (1995) Angiotensin II acdvates pp60c-src in vascular smooth muscle cells. Circ Res 77: 645–651
Johnston CI (1993) Angiotensin Converdng Enzyme Inhibition. In: Robertson JIS, Nichols MG (eds) The renin angiotensin system. Gower Medical Publication, pp 87.1–87.15
Johnston CI (1995) Angiotensin receptor antagonist: focus on losartan. Lancet 346: 1403–1407
Keidar S, Kaplan M, Hofman A, Aviram M (1995) Angiotensin II stimulates macrophage-mediated oxidation of low-density lipotproteins. Atherosclerosis 115: 201–215
Keidar S, Atdas J, Smith J, Breslow J, Hayek T (1997) The angiotensin II receptor antagonist, Losartan, inhibits LDL lipid perxodadon and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Com 236: 622–625
Levy D, Garrison RJ, Savage DD, Kanel WB, Castelli WP (1990) Prognostic implicadons of echocardio- graphically determined left ventricular mass in the framigham study N Engl J Med 322: 1561–1566
Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE (1995) The angiotensin II type 1 receptor associates with and sdmulates JAK2 in rat aortic smooth muscle cells. Nature 375: 247–250
Marrero MB, Schieffer B, Paxton WG, Schieffer E, Bernstein KE (1995) Electroporation of pp60c-src antibodies inhibits the angiotensin II acdvation of phospholipase-cl in rat vascular smooth muscle cells. J Biol Chem 270: 15734–15738
Milavetz JJ, Raya TE, Johnson C, Morkin E, Goldmann S (1996) Survival after myocardial infarction in rats: Captopril versus losartan. J Am Col Cardiol 27: 714–719
Pitt B, Segal R, Martinez FA for the ELITE Invesdgators (1997) Randomized trial of losartan versus Captopril in patinets over 65 with heart failure (Evaluadon of Losartan in the Elderly Study [ELITE]). Lancet 349: 747–752
Regitz-Zagrosek V, Neuss M, Fleck E (1995) Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Europ Heart J 16: 86–91
Ruzicka M, Yuan B, Leenen FHH (1994) Effects of Enalapril versus Losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 90: 484–491
Schieffer B, Wirger A, Meybrunn M, Seitz, Neragi S, Holtz J, Riede UN, Drexler H (1994) Comparadve effects of chronic ACE-inhibidon and ATI-blockade on cardiac remodeling after myocardial infaction. Circuladon 89: 2273–2282
Schieffer B, Wollert KC, Berchtold M, Saal K, Hornig B, Schieffer E, Riede UN, Drexler H (1995) Development and prevendon of skeletal muscle structural alteradons in experimental chronic heart failure. Am J Physiol 269: H1507-H1513
Schieffer B, Paxton WG, Bernstein KE, Marrero MB (1996) Angiotensin II controls p21 ras activity via pp60csrc in vascular smooth muscle cells. J Biol Chem 271: 10329–10333
Schieffer E, Herrmann G, Müller B, Günther R, Simon R, Studer R, Drexler H (1996) Expression of Angiotensin II forming enzymes in artherosclerotic human coronary arteries: selektive upregulation in unstable angina. Europ Heart J (Suppl 1): 2274
Schieffer B, Pax ton WG, Marrero MB, Bernstein KE (1996) Importance of tyrosine phosphorylation in Angiotensin II ATI receptor mediated signalling. Hypertension 27: 476–480
Schieffer B, Wyrwoll F, Wollert KC, Brauer N, Drexler H (1997a) Angiotensin II enhances the expression and release of interleukin-6 in human coronry smooth muscle cells: Involvement of the Jak-Stat pathway. Circulation Vol 97 (Suppl. II): -P635
Schieffer B, Wyrwoll F, Marrero MB, Drexler H (1997b) Gβ-Subnunit connects the JAK/STAT pathway via gpl30 and the p21ras/MAP Kinase cascade via SHC in angiotensin II stimulated vascular smooth muscle cells. Circulation 97 (Suppl. II): P773
Smits JFM, van Krimpen C, Schoemakers RG, Cleutjens JPM, Daemen MJAP(1992) Angiotensin II Receptor Blockade after Myocardial Infarction in Rats: Effect on Hemodynamics, Myocardial DNA Synthesis and Interstitial Collagen Content. J Cardiovasc Res 20: 272–278
Stoll M, Steckelings UM, Paul M, Bottari S, Metzger R, Unger T (1994) The angiotensin AT2-receptor mediates inhibition of coronary endothelial cells. J Clin Invest 95: 651–657
Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF (1991) Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12: 55–62
Timmermanns PBMWM, Wong PC, Chiu AT, Duncia JV (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205–230
Urata H, Boehm K, Philip A (1993) Human chymase: cellular localization and regional distribution of a major angiotensin Il-forming enzyme in the heart. J Clin Invest 91: 1269–1281
Whelton PK (1994) Epidemiology of Hypertension, Lancet 344: 101–104
Wollert KC, Studer R, Kästner S, Doerfer K, Schieffer E, Holubarsch C, Just HJ, Drexler H (1997) Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium. Circulation 95: 1910–1917
Yonezawa T, Umemoto S, Fujii A, Katayama K, Matzsaki M (1996) Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J Cardiovasc Pharmacol 27: 119–124
Zierhut W, Studer R, Laurent D, Kästner S, Allegrini P, Whitebread S, Cumin F, Baum HP, de Gasparo M, Drexler H (1996) Left ventricular wall stress and sarcoplasmatic reticulum Ca2-h-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and ATI-receptor blockade. J Cardiovasc Res 31: 758–768
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Schieffer, B., Drexler, H. (1999). Behandlung von Herzerkrankungen mit AT1-Rezeptorantagonisten. In: Dominiak, P., Unger, T. (eds) Angiotensin II AT1-Rezeptorantagonisten. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93705-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-93705-7_5
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-642-93706-4
Online ISBN: 978-3-642-93705-7
eBook Packages: Springer Book Archive